Hepatitis Monthly

Published by: Kowsar

Efficacy and Safety of Reinforced Versus Standard Vaccine Schedule Towards Hepatitis B In Chronic Kidney Disease: A Systematic Review and Meta-Analysis

Fabrizio Fabrizi 1 , * , Francesca Maria Donato 2 and Piergiorgio Messa 3
Authors Information
1 Division of Nephrology, Maggiore Hospital and IRCCS Foundation, Milano
2 Division of Gastroenterology, Maggiore Hospital and IRCCS Foundation, Milano
3 Division of Nephrology, Maggiore Hospital, University School of Medicine, Milano
Article information
  • Hepatitis Monthly: July 2017, 17 (7); e44179
  • Published Online: April 10, 2017
  • Article Type: Review Article
  • Received: November 21, 2016
  • Accepted: December 11, 2016
  • DOI: 10.5812/hepatmon.44179

To Cite: Fabrizi F, Maria Donato F, Messa P. Efficacy and Safety of Reinforced Versus Standard Vaccine Schedule Towards Hepatitis B In Chronic Kidney Disease: A Systematic Review and Meta-Analysis, Hepat Mon. 2017 ; 17(7):e44179. doi: 10.5812/hepatmon.44179.

Abstract
Copyright © 2017, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Context
2. Objective
3. Methods
4. Results
5. Discussion
Acknowledgements
Footnote
References
  • 1. Fabrizi F, Martin P. Hepatitis B virus infection in dialysis patients. Am J Nephrol. 2000; 20(1): 1-11[PubMed]
  • 2. Burdick RA, Bragg-Gresham JL, Woods JD, Hedderwick SA, Kurokawa K, Combe C, et al. Patterns of hepatitis B prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int. 2003; 63(6): 2222-9[DOI][PubMed]
  • 3. Finelli L, Miller JT, Tokars JI, Alter MJ, Arduino MJ. National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial. 2005; 18(1): 52-61[DOI][PubMed]
  • 4. Garcia Agudo R, Aoufi Rabih S, Barril Cuadrado G, Proy Vega B, Arias Arias A, Herruzo Gallego JA, et al. Spanish multicentre PIBHE study: Prevalence and immunization of chronic hepatitis B in haemodialysis patients in Spain. Nefrologia. 2016; 36(2): 126-32[DOI][PubMed]
  • 5. Johnson DW, Dent H, Yao Q, Tranaeus A, Huang CC, Han DS, et al. Frequencies of hepatitis B and C infections among haemodialysis and peritoneal dialysis patients in Asia-Pacific countries: analysis of registry data. Nephrol Dial Transplant. 2009; 24(5): 1598-603[DOI][PubMed]
  • 6. Igaki N, Nakaji M, Moriguchi R, Akiyama H, Tamada F, Oimomi M, et al. An outbreak of fulminant hepatitis B in immunocompromised hemodialysis patients. J Gastroenterol. 2003; 38(10): 968-76[DOI][PubMed]
  • 7. Recommendations for Preventing Transmission of Infections Among Chronic Hemodialysis Patients. MMWR Morb Mortal Wkly Rep. 2001; 50: 1-43
  • 8. Donati D, Gastaldi L. Controlled trial of thymopentin in hemodialysis patients who fail to respond to hepatitis B vaccination. Nephron. 1988; 50(2): 133-6[PubMed]
  • 9. Kapoor D, Aggarwal SR, Singh NP, Thakur V, Sarin SK. Granulocyte-macrophage colony-stimulating factor enhances the efficacy of hepatitis B virus vaccine in previously unvaccinated haemodialysis patients. J Viral Hepat. 1999; 6(5): 405-9[PubMed]
  • 10. Marangi AL, Giordano R, Montanaro A, De Padova F, Schiavone MG, Dongiovanni G, et al. Hepatitis B virus infection in chronic uremia: long-term follow-up of a two-step integrated protocol of vaccination. Am J Kidney Dis. 1994; 23(4): 537-42[PubMed]
  • 11. Fabrizi F, Di Filippo S, Marcelli D, Guarnori I, Raffaele L, Crepaldi M, et al. Recombinant hepatitis B vaccine use in chronic hemodialysis patients. Long-term evaluation and cost-effectiveness analysis. Nephron. 1996; 72(4): 536-43[PubMed]
  • 12. DaRoza G, Loewen A, Djurdjev O, Love J, Kempston C, Burnett S, et al. Stage of chronic kidney disease predicts seroconversion after hepatitis B immunization: earlier is better. Am J Kidney Dis. 2003; 42(6): 1184-92[PubMed]
  • 13. Moher D, Liberati A, Tetzlaff J, Altman DG, Prisma Group . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009; 62(10): 1006-12[DOI][PubMed]
  • 14. Poynard T, Conn HO. The retrieval of randomized clinical trials in liver disease from the medical literature. Controlled Clinical Trials. 1985; 6(4): 271-9[DOI]
  • 15. Viswanathan M, Ansari MT, Berkman ND, Chang S, Hartling L, McPheeters M, et al. Methods Guide for Effectiveness and Comparative Effectiveness Reviews. 2008; [PubMed]
  • 16. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials. 1986; 7(3): 177-88[DOI]
  • 17. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003; 327(7414): 557-60[DOI][PubMed]
  • 18. Petitti DB. Approaches to heterogeneity in meta-analysis. Stat Med. 2001; 20(23): 3625-33[PubMed]
  • 19. Galbraith RF. A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med. 1988; 7(8): 889-94[PubMed]
  • 20. Klein S, Simes J, Blackburn GL. Total parenteral nutrition and cancer clinical trials. Cancer. 1986; 58(6): 1378-86[DOI]
  • 21. Benhamou E, Courouce AM, Jungers P, Laplanche A, Degos F, Brangier J, et al. Hepatitis B vaccine: randomized trial of immunogenicity in hemodialysis patients. Clin Nephrol. 1984; 21(3): 143-7[PubMed]
  • 22. Aronoff GR, Maxwell DR, Batteiger BE, Fineberg NS. Hepatitis B virus vaccine: a randomized trial of a reduced dose regimen in hemodialysis patients. Am J Kidney Dis. 1985; 6(3): 170-2[PubMed]
  • 23. Lelie PN, Reesink HW, de Jong-van Manen ST, Dees PJ, Reerink-Brongers EE. Immune response to a heat-inactivated hepatitis B vaccine in patients undergoing hemodialysis. Enhancement of the response by increasing the dose of hepatitis B surface antigen from 3 to 27 micrograms. Arch Intern Med. 1985; 145(2): 305-9[PubMed]
  • 24. Seaworth B, Drucker J, Starling J, Drucker R, Stevens C, Hamilton J. Hepatitis B vaccines in patients with chronic renal failure before dialysis. J Infect Dis. 1988; 157(2): 332-7[PubMed]
  • 25. Bruguera M, Cremades M, Rodicio JL, Alcazar JM, Oliver A, Del Rio G, et al. Immunogenicity of a yeast-derived hepatitis B vaccine in hemodialysis patients. Am J Med. 1989; 87(3A): 30S-2S[PubMed]
  • 26. Mitwalli A. Responsiveness to hepatitis B vaccine in immunocompromised patients by doubling the dose scheduling. Nephron. 1996; 73(3): 417-20[PubMed]
  • 27. Mauri JM, Valles M. Effects of recombinant interleukin-2 and revaccination for hepatitis B in previously vaccinated, non-responder, chronic uraemic patients. Collaborative Group of Girona. Nephrol Dial Transplant. 1997; 12(4): 729-32[PubMed]
  • 28. Deniz Ayli M, Ensari C, Ayli M, Mandiroglu F, Mut S. Effect of oral levamisole supplementation to hepatitis B vaccination on the rate of immune response in chronic hemodialysis patients. Nephron. 2000; 84(3): 291-2[PubMed]
  • 29. McNulty CA, Bowen JK, Williams AJ. Hepatitis B vaccination in predialysis chronic renal failure patients a comparison of two vaccination schedules. Vaccine. 2005; 23(32): 4142-7[DOI][PubMed]
  • 30. Chow KM, Law MC, Leung CB, Szeto CC, Li PK. Antibody response to hepatitis B vaccine in end-stage renal disease patients. Nephron Clin Pract. 2006; 103(3)-93[DOI][PubMed]
  • 31. Chow KM, Lo SH, Szeto CC, Yuen SK, Wong KS, Kwan BC, et al. Extra-high-dose hepatitis B vaccination does not confer longer serological protection in peritoneal dialysis patients: a randomized controlled trial. Nephrol Dial Transplant. 2010; 25(7): 2303-9[DOI][PubMed]
  • 32. Jadoul M, Goubau P. Is anti-hepatitis B virus (HBV) immunization successful in elderly hemodialysis (HD) patients? Clin Nephrol. 2002; 58(4): 301-4[PubMed]
  • 33. Khedmat H, Aghaei A, Ghamar-Chehreh ME, Agah S. Sex bias in response to hepatitis B vaccination in end-stage renal disease patients: Meta-analysis. World J Nephrol. 2016; 5(1): 115-24[DOI][PubMed]
  • 34. Fernandez E, Betriu MA, Gomez R, Montoliu J. Response to the hepatitis B virus vaccine in haemodialysis patients: influence of malnutrition and its importance as a risk factor for morbidity and mortality. Nephrol Dial Transplant. 1996; 11(8): 1559-63[PubMed]
  • 35. Navarro JF, Teruel JL, Mateos ML, Marcen R, Ortuno J. Antibody level after hepatitis B vaccination in hemodialysis patients: influence of hepatitis C virus infection. Am J Nephrol. 1996; 16(2): 95-7[PubMed]
  • 36. Ahuja TS, Kumar S, Mansoury H, Rodriguez H, Kuo YF. Hepatitis B vaccination in human immunodeficiency virus-infected adults receiving hemodialysis. Kidney Int. 2005; 67(3): 1136-41[DOI][PubMed]
  • 37. Alavian SM, Tabatabaei SV. The effect of diabetes mellitus on immunological response to hepatitis B virus vaccine in individuals with chronic kidney disease: A meta-analysis of current literature. Vaccine. 2010; 28(22): 3773-7[DOI][PubMed]
  • 38. Sennesael JJ, Van der Niepen P, Verbeelen DL. Treatment with recombinant human erythropoietin increases antibody titers after hepatitis B vaccination in dialysis patients. Kidney Int. 1991; 40(1): 121-8[PubMed]
  • 39. Pol S, Legendre C, Mattlinger B, Berthelot P, Kreis H. Genetic basis of nonresponse to hepatitis B vaccine in hemodialyzed patients. J Hepatol. 1990; 11(3): 385-7[PubMed]
  • 40. Jibani MM, Heptonstall J, Walker AM, Bloodworth LO, Howard AJ. Hepatitis B immunization in UK renal units: failure to put policy into practice. Nephrol Dial Transplant. 1994; 9(12): 1765-8[PubMed]
  • 41. Mulley WR, Le ST, Ives KE. Primary seroresponses to double-dose compared with standard-dose hepatitis B vaccination in patients with chronic kidney disease: a systematic review and meta-analysis. Nephrol Dial Transplant. 2016; [DOI][PubMed]
  • 42. Chen YC, Su YC, Li CY, Wu CP, Lee MS. A nationwide cohort study suggests chronic hepatitis B virus infection increases the risk of end-stage renal disease among patients in Taiwan. Kidney Int. 2015; 87(5): 1030-8[DOI][PubMed]
  • 43. Wu T, Li Y, Bian Z, Liu G, Moher D. Randomized trials published in some Chinese journals: how many are randomized? Trials. 2009; 10: 46[DOI][PubMed]
  • 44. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet. 1998; 352(9128): 609-13[DOI][PubMed]
  • 45. Miller ER, Alter MJ, Tokars JI. Protective effect of hepatitis B vaccine in chronic hemodialysis patients. Am J Kidney Dis. 1999; 33(2): 356-60[PubMed]
  • 46. Surquin M, Tielemans CL, Kulcsar I, Ryba M, Voros P, Mat O, et al. Rapid, enhanced, and persistent protection of patients with renal insufficiency by AS02(V)-adjuvanted hepatitis B vaccine. Kidney Int. 2010; 77(3): 247-55[DOI][PubMed]
  • 47. Fabrizi F, Tarantino A, Castelnovo C, Martin P, Messa P. Recombinant Hepatitis B Vaccine Adjuvanted With AS04 in Dialysis Patients: A Prospective Cohort Study. Kidney Blood Press Res. 2015; 40(6): 584-92[DOI][PubMed]
  • 48. Weinstein T, Chagnac A, Boaz M, Ori Y, Herman M, Zevin D, et al. Improved immunogenicity of a novel third-generation recombinant hepatitis B vaccine in patients with end-stage renal disease. Nephron Clin Pract. 2004; 97(2)-72[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments